Truist Financial Corp raised its stake in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 20.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,499 shares of the company’s stock after buying an additional 18,644 shares during the quarter. Truist Financial Corp owned about 0.06% of Catalent worth $7,129,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in the company. FNY Investment Advisers LLC purchased a new stake in Catalent during the first quarter worth $34,000. Covestor Ltd boosted its holdings in Catalent by 84.9% during the first quarter. Covestor Ltd now owns 562 shares of the company’s stock worth $62,000 after buying an additional 258 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Catalent in the 1st quarter valued at about $48,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Catalent during the 4th quarter worth approximately $34,000. Finally, Parkside Financial Bank & Trust increased its stake in shares of Catalent by 53.2% during the first quarter. Parkside Financial Bank & Trust now owns 760 shares of the company’s stock worth $50,000 after purchasing an additional 264 shares in the last quarter.
Catalent Trading Down 0.8 %
NYSE:CTLT opened at $45.97 on Friday. Catalent, Inc. has a 12 month low of $31.45 and a 12 month high of $110.97. The company has a quick ratio of 1.34, a current ratio of 1.84 and a debt-to-equity ratio of 0.91. The firm has a market cap of $8.29 billion, a price-to-earnings ratio of 208.96, a P/E/G ratio of 5.29 and a beta of 1.23. The company’s 50 day moving average is $44.68 and its 200-day moving average is $51.98.
Insider Activity at Catalent
In related news, CEO Alessandro Maselli sold 1,485 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $47.13, for a total value of $69,988.05. Following the completion of the sale, the chief executive officer now owns 86,101 shares of the company’s stock, valued at $4,057,940.13. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 1,889 shares of company stock valued at $89,248 over the last ninety days. 0.58% of the stock is owned by insiders.
Analyst Ratings Changes
Several research firms have recently weighed in on CTLT. Robert W. Baird increased their price target on shares of Catalent from $35.00 to $47.00 in a research note on Tuesday, June 13th. UBS Group cut their target price on Catalent from $60.00 to $55.00 in a research report on Tuesday, June 13th. Jefferies Financial Group downgraded shares of Catalent from a “buy” rating to a “hold” rating and decreased their price objective for the company from $45.00 to $44.00 in a research note on Wednesday, June 14th. Royal Bank of Canada reiterated an “outperform” rating and issued a $49.00 price target on shares of Catalent in a research report on Friday, June 30th. Finally, TheStreet downgraded Catalent from a “c” rating to a “d+” rating in a report on Monday, June 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $56.25.
Check Out Our Latest Stock Report on CTLT
About Catalent
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Recommended Stories
- Five stocks we like better than Catalent
- Stock Market Upgrades: What Are They?
- Investing in Coffee: 3 Great Strategies to Consider
- How to Invest in Biotech Stocks
- 5 Best Stocks to Buy in a Bear Market
- What is the Australian Securities Exchange (ASX)
- 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
